Health Care · S&P 500
Bristol Myers Squibb
A large pharmaceutical company developing oncology, immunology, and cardiovascular drugs. S&P 500 constituent. Sector: Health Care (Pharmaceuticals). Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
BMY Updated Jul 11, 2026 2 AI consumers· 1 recurring
Per the valuechain.wiki graph, Bristol Myers Squibb is directly linked to 1 companies (0 supply, 1 revenue relationships) and reaches 2 companies within two hops; the links are backed by 1 dated sources, 1 of them primary filings (as of 2026-07-11).
Annual return · 2026-07-10'21+2.9%'22+19%'23-26.1%'24+15.8%'25+0.1%YTD+10.4%
Financials & Segments
- Total revenue · ~$48B (FY2024)
- Segments · Oncology · Hematology · Immunology & Cardiovascular
Revenue from
- ABL Bio Medium confidence
Supplies Opdivo (nivolumab) to ABL Bio's ABL111 gastric-cancer bispecific triple-combination trial; a clinical combination-supply arrangement with undisclosed value.
Pays to
No refined links yet.
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Lilly (Eli) | lead2 | +66.1 | +34.3 | +60.9 | +33.3 | +40.2 | +11 |
| ABL Bio | lead1 | +15.9 | -31.3 | +14.2 | +65.2 | +443.9 | -58.6 |
| Bristol Myers Squibb | node | +2.9 | +19 | -26.1 | +15.8 | +0.1 | +10.4 |
YTD as of 2026-07-10 · source: Yahoo Finance